The short answer
Ginkgo leaf products warrant a bleeding precaution with heparin, although the exact risk is uncertain. Regulatory guidance recommends medical consultation with anticoagulants; small trials with other treatments have found no added platelet effect.
What this answer covers
Oral Ginkgo biloba leaf extracts or leaf powder with injected unfractionated heparin; seeds and injected ginkgo combination medicines are outside this scope.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- heparin
Regulatory guidance supports a precaution
The European ginkgo monograph says covered preparations may increase bleeding susceptibility and should be reviewed with a doctor during anticoagulant treatment. Heparin already carries a bleeding risk, but the monograph does not quantify a heparin-specific interaction.
Controlled studies include null findings
A four-week study of EGb761 with aspirin in older adults found no detected added platelet effect or excess bleeding reports. Another small commercial-product study also found no platelet effect. These results limit a universal harm claim but do not establish safety during heparin treatment.
Surgery advice is a different timing question
For covered extracts, the monograph gives a precaution to discontinue ginkgo three to four days before surgery. This is a procedure-related plan for the clinical team, not evidence that spacing ginkgo and heparin doses by hours prevents an interaction.
Use a product-specific plan
Tell the heparin team about the exact supplement before starting or changing it. Report unusual bleeding or bruising promptly; serious bleeding, black stools or vomiting blood needs urgent assessment. Do not change prescribed heparin yourself. Discuss planned procedures as well as the exact leaf preparation; do not substitute advice about other anticoagulants or injected ginkgo mixtures.
Evidence and practical considerations
Side effects & toxicity
Indirect regulatory anticoagulant precaution; null controlled platelet studies and absence of exact heparin outcomes constrain the claim.
- Exact scope
- Oral Ginkgo biloba leaf extracts or leaf powder with injected unfractionated heparin; seeds and injected ginkgo combination medicines are outside this scope. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified preparation.
Covered leaf preparations may increase bleeding susceptibility; anticoagulant co-use requires consultation. Gives a three-to-four-day presurgical discontinuation precaution for covered extracts.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Class-level precaution, not an exact heparin trial. Presurgical guidance is not proof that separating same-day doses prevents interaction.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Older adults with peripheral arterial disease or cardiovascular risk; platelet-function analyses included 55 participants.
No detected between-group difference in platelet tests; bleeding/bruising reports were infrequent and similar.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Small sample; different antithrombotic mechanism from heparin and no assurance for all products or high-risk patients.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten adult volunteers.
No PFA-100 platelet-function effect from any tested herb; aspirin control inhibited function.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Only ten volunteers and a laboratory platelet test. Not clinical bleeding surveillance in heparin recipients; original experimental component used, not the accompanying review.
Research assessment: · Open full citations ↗
Timing & monitoring
Narrow to clinical consultation and covered-extract presurgical discontinuation guidance, not universal avoidance or an effective same-day spacing rule.
- Exact scope
- Oral Ginkgo biloba leaf extracts or leaf powder with injected unfractionated heparin; seeds and injected ginkgo combination medicines are outside this scope. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified preparation.
Covered leaf preparations may increase bleeding susceptibility; anticoagulant co-use requires consultation. Gives a three-to-four-day presurgical discontinuation precaution for covered extracts.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Class-level precaution, not an exact heparin trial. Presurgical guidance is not proof that separating same-day doses prevents interaction.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Older adults with peripheral arterial disease or cardiovascular risk; platelet-function analyses included 55 participants.
No detected between-group difference in platelet tests; bleeding/bruising reports were infrequent and similar.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Small sample; different antithrombotic mechanism from heparin and no assurance for all products or high-risk patients.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten adult volunteers.
No PFA-100 platelet-function effect from any tested herb; aspirin control inhibited function.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Only ten volunteers and a laboratory platelet test. Not clinical bleeding surveillance in heparin recipients; original experimental component used, not the accompanying review.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact-pair article preserving route, formulation, clinical-outcome and laboratory-endpoint distinctions. | |
| Research summary published |
Article revision: 09e11cf2963294b6
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.